News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Cardiovascular disease news

Show

From To
Hepatitis and HIV
Hepatitis C does not raise risk of heart disease or cancers in people with HIV

Hepatitis C coinfection does not increase the risk of cardiovascular disease or non-AIDS cancers in people with HIV, an analysis of the large Eurosida cohort published in

Published
19 July 2019
By
Keith Alcorn
Cardiovascular disease
HIV infection may increase heart failure and stroke risk

A Journal of the American Heart Association analysis of information from a large health insurance database reveals that people living with HIV have an elevated risk of developing cardiovascular disease (CVD), particularly heart failure and stroke. The findings indicate that increased efforts to protect patients' cardiovascular health are needed.

Published
03 July 2019
From
EurekAlert
Cardiovascular disease
Efavirenz Dose Reduction Improves Lipid Profile in Adults With HIV-1

The researchers concluded that “a reduced dose of efavirenz (a 400 mg dose is now recommended as an alternative first-line regimen also by [World Health Organization] can lead to a significant decline in total cholesterol and LDL and should be used especially in patients with cardiovascular or metabolic comorbidities.”

Published
19 June 2019
From
Infectious Disease Advisor
Cardiovascular disease
Performance of CVD Risk Prediction Algorithms in People Living With HIV

Algorithms may help predict cardiovascular disease (CVD) risk in people living with HIV (PLWHIV), according to a study published in the Journal of Acquired Immune Deficiency Syndromes.

Published
11 June 2019
From
Infectious Disease Advisor
Cardiovascular disease
American Heart Association Scientific Statement on CVD and HIV

A new scientific statement from the American Heart Association (AHA) provides "pragmatic" recommendations on how to approach cardiovascular disease (CVD) prevention and management in the growing number of people living with HIV infection.

Published
04 June 2019
From
Medscape (requires free registration)
Cardiovascular disease
As HIV patients live longer, heart disease might be their next challenge

As people with HIV live longer, they also find themselves at higher risk for heart attack, stroke and other types of cardiovascular disease. A new American Heart Association report hopes to raise awareness about that connection, along with pointing out cardiovascular disease prevention and treatment strategies for an emerging population with unique concerns researchers have only begun to explore.

Published
04 June 2019
From
American Heart Association
Cardiovascular disease
Subclinical findings may explain heart failure risk in women with HIV

Asymptomatic aging women with HIV who are being treated with ART exhibited increased myocardial fibrosis and reduced diastolic function compared with women who are not infected with HIV, according to a study results.

Published
07 May 2019
From
Healio
Side-effects
Weight gain with new antiretrovirals: It's complicated

South Africa’s next big shift in our antiretroviral programme is to replace efavirenz with a newish drug called dolutegravir. The Department of Health is pleased at the prospect of a safer, more robust and, amazingly, cheaper drug. But last year, the first reports surfaced that people using it were gaining weight.

Published
15 April 2019
From
Spotlight
Lipodystrophy
The impact of older antiretrovirals on fat redistribution and cardiovascular risk factors may be irreversible

Fat redistribution in people with HIV who have ever taken thymidine analogues and/or didanosine (TA/ddI) can persist through time, while increasing cardiovascular risk factors, according to a Danish

Published
21 March 2019
By
Alain Volny-Anne
Drug-resistant TB
TB CAB statement on safety of using bedaquiline and delamanid together

he Global TB Community Advisory Board (TB CAB) welcomes the important finding from the AIDS Clinical Trials Group Deliberate Trial that newer drugs bedaquiline and delamanid are safe to use together. These findings should erase any remaining reluctance to use these two important drugs together, as the benefits of these safer drugs outweigh the risks--especially for patients with drug-resistant TB who have few other treatment options.

Published
14 March 2019
From
TB Online
← First12345...32Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.